Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trialKeith J. Chappell, Trent P. Munro|The Lancet Infectious Diseases|2021Cited by 119
Characterization and comparison of novel adjuvants for a prefusion clamped MERS vaccineJake S. O’Donnell, Keith J. Chappell|Frontiers in Immunology|2022Cited by 17